Company Overview
Company Type: Public Company
Website: www.bioniklabs.com
Number of Employees: 12
Ticker: BNKL (OTCPK)
Year Founded: 2010


Business Description
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.

Financial Information (Currency: CAD, in mm) 
Total Revenue
2.5
Market Capitalization
4.1
TEV/Total Revenue
2.8x
EBITDA
(6.4)
Total Enterprise Value
6.8
TEV/EBITDA
NM
EBIT
(6.5)
Cash & ST Invst.
0.6
P/Diluted EPS Before Extra
NM
Net Income
(6.8)
Total Debt
3.3
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
4.6
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Russo, Richard Paul
CEO, President & Director
Prywata, Michal 
Co-Founder & Director
Gonsalves, Daniel 
Executive VP & CFO
Smathers, John 
Director of Operations

Key Board Members
Name
Title
Russo, Richard Paul
CEO, President & Director
Prywata, Michal 
Co-Founder & Director
Gaston-Dreyfus, Remi 
Independent Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
80 Coolidge Hill Road | Watertown, MA | 02472 | United States
Phone: 617 926 4800   

Current and Pending Investors
Abrahams LLP, Céleste Management SA, DMZ Ventures, ECI, Inc., Fidelity Clearing Canada ULC, Garden State Securities, Inc., Gd Holding, Ginger Capital Management Limited, Goldenmount Capital International Inc., Investment Arm, Helicopter Express Inc., Investment Advisory Group, LLC, JW Asset Management, LLC, Lifestyle Healthcare LLC, Lombard International Assurance S.A., Merriman Capital, Inc., Oceanair Environmental LLC, Perspecta Trust LLC, Providence Corporation, Quest Trust Company, Inc., RGD Investissements, Solomar Sa, Spg Royalties Inc., Vishay Intertechnology, Inc. (NYSE:VSH)

Prior Investors
FundRx, Inc, Huntington Electric, Inc., Quest IRA, Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.33
Market Cap (mm)
4.1
Open
 0.33
Shares Out. (mm)
12.6
Previous Close
 0.33
Float %
29.5%
Change on Day
(0.01)
Shares Sold Short (mm)
0.0
Change % on Day
(4.0)%
Dividend Yield %
-
Day High/Low
 0.33/ 0.33
Diluted EPS Excl. Extra Items
(0.98)
52 wk High/Low
 3.97/ 0.33
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0025
Avg 3M Dly Vlm (mm)
0.0021
Beta 5Y
(0.81)


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Florida Rehabilitation Center
As of September 8, 2022, Florida Rehabilitation Center was acquired by Bionik Laboratories Corp. Florida Rehabilitation Center comprises a rehabilitation center. The asset is located in the United States.

United States and Canada
Health Care Facilities
-
-
-
Bionik, Inc.
Bionik, Inc. designs, develops, and markets robotic tools for neurorehabilitation professionals, and patients and their families. It offers interactive therapy systems; a robot for grasp and release training needs; and an exoskeletal arm robot for clinical research aspects. The company was founded in 1998 and is based in Watertown, Massachusetts. As of April 21, 2016, Bionik, Inc. operates as a subsidiary of Bionik Laboratories Corp.

United States and Canada
Health Care Equipment
2.00
0.00
1.00
Bionik Laboratories Corp.
Bionik Laboratories Corp. does not have significant operations. The company intends to seek new business opportunities, including the acquisition of, or merger with, an existing business. Previously, it provided consulting and management services to the dental industry. The company was formerly known as Drywave Technologies, Inc. and changed its name to Bionik Laboratories Corp. in February 2015. Bionik Laboratories Corp. was founded in 2010 and is based in Washington Boro, Pennsylvania. As of February 26, 2015, Bionik Laboratories Corp. was acquired by Bionik Laboratories Inc., in a reverse merger transaction.

United States and Canada
Health Care Services
0.00
0.00
0.00
China Bionik Medical Rehabilitation Technology Ltd

Asia / Pacific
-
-
-
-
Tower Aquatic LLC
Tower Aquatic LLC was incorporated in 2022 and is based in Watertown, Massachusetts. Tower Aquatic LLC operates as a subsidiary of Bionik Laboratories Corp.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-13-2023
-
Private Placement
Target
Bionik Laboratories Corp. (OTCPK:BNKL)


2.00
Apr-20-2023
Apr-20-2023
Private Placement
Target
Bionik Laboratories Corp. (OTCPK:BNKL)


0.25
Feb-16-2023
Feb-16-2023
Private Placement
Target
Bionik Laboratories Corp. (OTCPK:BNKL)


0.50
Nov-14-2022
Nov-14-2022
Private Placement
Target
Bionik Laboratories Corp. (OTCPK:BNKL)
Gd Holding

0.40
Sep-08-2022
Sep-08-2022
Merger/Acquisition
Buyer
Florida Rehabilitation Center
Bionik Laboratories Corp. (OTCPK:BNKL)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-27-2023
Executive/Board Changes - Other
Bionik Laboratories Corp. Announces Executive Changes
Jun-21-2023
Shelf Registration Filings
Bionik Laboratories Corp. has withdrawn its Shelf Registration dated July 14, 2017 in the amount of $4.18 million.
Jun-21-2023
Auditor Going Concern Doubts
Bionik Laboratories Corp. Auditor Raises 'Going Concern' Doubt
Jun-15-2023
Client Announcements
Bionik Laboratories Corp. Expands Its Partnership With Lifepoint Health With the Installation of InMotion® Robotic Devices at Four New Locations
Jun-13-2023
Private Placements
Bionik Laboratories Corp. announced that it expects to receive $2 million in funding

Competitors
CYBERDYNE Inc. (TSE:7779), Ekso Bionics Holdings, Inc. (NasdaqCM:EKSO), Hocoma AG, Honda Motor Co., Ltd. (TSE:7267), Motorika Medical (USA) Inc., Parker-Hannifin Corporation (NYSE:PH), Tyromotion GmbH

M&A Advisors
Fasken Martineau DuMoulin LLP, Ruskin Moscou Faltischek, P.C.


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Fasken Martineau DuMoulin LLP, Ruskin Moscou Faltischek, P.C.
Private Placement Advisors
Columbus Advisory Group, Ltd., Fasken Martineau DuMoulin LLP, Garden State Securities, Inc., Merriman Capital, Inc., Ruskin Moscou Faltischek, P.C.
Public Offering Advisors
MNP LLP, Ruskin Moscou Faltischek, P.C.


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:50 AM
BNKL
Bionik Laboratories Corp 2023_10_05
Reports
14
MarketLine

Sep 14, 2023 06:01 AM
BNKL
Bionik Laboratories Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
84
GlobalData

Sep 11, 2023 01:21 AM
BNKL
Bionik Laboratories Corp (BNKL.OTC) - Financial Analysis Review
Reports
153
S&P Global Compustat

Sep 07, 2023 03:42 AM
BNKL
Bionik Laboratories Corp 2023_09_07
Reports
14
GlobalData

Aug 29, 2023 01:45 AM
BNKL
Bionik Laboratories Corp (BNKL.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
38
S&P Global Compustat

Jul 06, 2023 03:19 AM
BNKL
Bionik Laboratories Corp 2023_07_06
Reports
14
GlobalData

Jun 13, 2023 10:22 PM
BNKL
Bionik Laboratories Corp (BNKL.OTC) - Financial Analysis Review
Reports
153
S&P Global Compustat

Jun 01, 2023 04:51 AM
BNKL
Bionik Laboratories Corp 2023_06_01
Reports
14
GlobalData

May 09, 2023 04:00 AM
BNKL
Bionik Laboratories Corp (BNKL.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
38
S&P Global Compustat

May 04, 2023 03:40 AM
BNKL
Bionik Laboratories Corp 2023_05_04
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Gaston-Dreyfus, Remi 

4,879,754

38.75

1.6

Jun-16-2023


RGD Investissements

1,457,178

11.57

0.5

Jun-13-2023


Céleste Management SA

1,315,605

10.45

0.4

Jun-16-2023


Star Sci

1,109,271

8.81

0.4

Jun-16-2023


SFP Capital

1,032,244

8.20

0.3

Jun-16-2023


Dassault, Olivier 

693,963

5.51

0.2

Jun-16-2023


Prywata, Michal 

667,591

5.30

0.2

Jun-16-2023


Lombard International Assurance S.A., Asset Management Arm

99,251

0.79

0.0

Jun-16-2023


Auberton-Herve, Andre-Jacques 

95,149

0.76

0.0

Jun-16-2023


4A Consulting And Engineering

10,693

0.08

0.0

Jun-16-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Gaston-Dreyfus, Remi 
4,879,754
3,283,433
Star Sci
1,109,271
730,269
Prywata, Michal 
667,591
617,615
SFP Capital
1,032,244
422,222
Céleste Management SA
1,315,605
372,333

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
APOLLO (Future), ARKE, Chronos (Future), Distribution of Morning Walk Lower Body Rehabilitation Products, InMotion AnkleBot (Future), InMotion ARM, InMotion Arm Interactive Robotic System, InMotion ARM Interactive Therapy Systems, InMotion ARM/HAND, InMotion Connect, InMotion Home (Future), InMotion WRIST


Upcoming Events
Date/Time
Type
Nov-09-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jun-27-2023
Jun-22-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (5.02, 9.01)
195 KB
Jun-21-2023
Mar-31-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
10-K
9 MB
Jun-16-2023
Jun-13-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (1.01, 2.03, 3.02, 8.01, 9.01)
371 KB
Jun-16-2023
Jun-09-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (3.02, 9.01)
192 KB
Jun-15-2023
Jun-15-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (7.01, 9.01)
217 KB
May-23-2023
May-23-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (7.01, 9.01)
212 KB
May-04-2023
May-04-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (7.01, 9.01)
211 KB
Apr-26-2023
Apr-20-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (1.01, 2.03, 3.02, 9.01)
199 KB
Feb-23-2023
Feb-16-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (1.01, 2.03, 3.02, 9.01)
306 KB
Feb-08-2023
Feb-08-2023
Bionik Laboratories Corp. (OTCPK:BNKL)
SEC
8-K (2.02, 9.01)
345 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Lombard International Assurance S.A., Asset Management Arm
Jun-13-2023
Common Stock
3,102,878
2,546,433
Derivative Exercise and Retained Stock
867.47
Form 4
Star Sci
Jun-13-2023
Common Stock
186,111
152,735
Derivative Exercise and Retained Stock
20.16
Form 4
Lombard International Assurance S.A., Asset Management Arm
Jun-09-2023
Common Stock
180,555
148,176
Open Market Acquisition
5.50
Form 4
Star Sci
Jun-09-2023
Common Stock
650,000
533,434
Open Market Acquisition
141.53
Form 4
Matine, Charles  (Former Independent Director)
Jun-09-2023
Common Stock
180,555
148,176
Open Market Acquisition
683.14
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Russo, Richard Paul
CEO, President & Director
(617) 926-4800
-
rrusso@bioniklabs.com
Prywata, Michal 
Co-Founder & Director
617 926 4800
-

Gaston-Dreyfus, Remi 
Independent Director
617 926 4800
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Russo, Richard Paul
CEO, President & Director
(617) 926-4800
-
rrusso@bioniklabs.com
Prywata, Michal 
Co-Founder & Director
617 926 4800
-

Gonsalves, Daniel 
Executive VP & CFO
617 926 4800
-

Smathers, John 
Director of Operations
617 926 4800
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
